ExonHit Therapeutics S.A. selected to participate in the European IMI consortium

“The participation of ExonHit in this European initiative further validates our SpliceArray™ technology and our R&D expertise in Alzheimer’s disease”

ExonHit Therapeutics S.A. (Paris:ALEHT) (Alternext: ALEHT) is pleased to announce that it has been chosen to participate in the European Innovative Medicines Initiative (IMI) consortium focused on identifying biomarkers for Alzheimer’s disease (PharmaCog).

PharmaCog focuses on translational science and harmonization of research tools. Ultimately PharmaCog should provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines.

“ExonHit’s unique understanding of transcriptomic analysis will be critical to PharmaCog as it could enable the identification of blood-based markers of disease presence and progression,” said Professor Olivier Blin, Head of the Center of Clinical Pharmacology and Therapeutic Evaluations of Marseille Hospital. “Such markers are critical in drug development because they provide scientists with greater insights on how results found during preclinical testing are likely to be reproduced in the clinic.”

“The participation of ExonHit in this European initiative further validates our SpliceArray™ technology and our R&D expertise in Alzheimer’s disease,” stated Loïc Maurel, M.D., President of the Management Board of ExonHit Therapeutics. “Alzheimer’s disease is an area of prime interest for ExonHit and the experience we have gained developing AclarusDx™ Alzheimer’s test, our blood-based test to select or stratify patients suffering from Alzheimer’s disease and EHT 0202, our Phase 2 compound for Alzheimer’s disease, will certainly benefit PharmaCog initiative.”